Raymond James & Associates boosted its position in shares of Azenta, Inc. (NASDAQ:AZTA – Get Rating) by 36.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 58,512 shares of the company’s stock after acquiring an additional 15,777 shares during the quarter. Raymond James & Associates’ holdings in Azenta were worth $2,508,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the company. Glassman Wealth Services bought a new position in Azenta in the second quarter worth approximately $25,000. Quadrant Capital Group LLC purchased a new stake in Azenta in the second quarter valued at approximately $26,000. Castle Wealth Management LLC purchased a new stake in shares of Azenta during the second quarter worth $34,000. Assetmark Inc. purchased a new stake in shares of Azenta during the second quarter worth $39,000. Finally, SeaCrest Wealth Management LLC acquired a new position in shares of Azenta during the second quarter worth $48,000. Hedge funds and other institutional investors own 96.42% of the company’s stock.
Azenta Price Performance
Shares of NASDAQ:AZTA opened at $55.75 on Friday. The company has a market capitalization of $3.85 billion, a price-to-earnings ratio of 1.97 and a beta of 1.61. The firm’s 50 day simple moving average is $58.83 and its 200 day simple moving average is $55.69. Azenta, Inc. has a fifty-two week low of $37.61 and a fifty-two week high of $93.39.
Wall Street Analyst Weigh In
AZTA has been the subject of several recent research reports. KeyCorp decreased their target price on shares of Azenta from $90.00 to $70.00 and set an “overweight” rating for the company in a research note on Monday, October 24th. Needham & Company LLC increased their price target on shares of Azenta from $74.00 to $78.00 and gave the company a “buy” rating in a research report on Tuesday, November 15th. TheStreet raised shares of Azenta from a “d+” rating to a “c-” rating in a research note on Tuesday, December 13th. Finally, Stephens boosted their target price on shares of Azenta from $60.00 to $65.00 in a research report on Thursday, November 17th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $72.60.
Azenta, Inc is a provider of life sciences sample exploration and management solutions for the life sciences market. It operates through the Life Sciences Products and Life Sciences Services segments. The Life Sciences Products segment is involved in automated cold storage solutions for biological and chemical compound samples.
- Get a free copy of the StockNews.com research report on Azenta (AZTA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.